Private endoscopic DCR for watery eye UK 2026 — transnasal lacrimal bypass surgery

What is endoscopic dacryocystorhinostomy (DCR)?

Dacryocystorhinostomy (DCR) is a tear-drainage bypass operation. When tears cannot pass from the lacrimal sac into the nose through the obstructed nasolacrimal duct, they back up and overflow onto the face (epiphora) and the sac can become chronically infected (dacryocystitis) or distended (mucocoele). DCR solves this by creating a new, wide direct opening between the lacrimal sac and the nasal cavity through a bony osteotomy in the lacrimal bone and frontal process of the maxilla — effectively bypassing the obstructed duct altogether. Endoscopic DCR is the modern, scarless approach: the entire operation is performed inside the nose, using rigid nasal endoscopes (0, 30 and 45 degree, typically 4 mm) passed through the operative nostril, with no skin incision and no visible scar.

The operation is performed under day-case general anaesthetic in the UK in 2026, with controlled hypotensive technique to optimise the surgical field. The lateral nasal wall mucosa is incised and elevated as a posterior-based flap above the axilla of the middle turbinate, exposing the lacrimal bone and frontal process of the maxilla overlying the lacrimal sac. A wide bony osteotomy (typically 12-15 mm vertical, 8-10 mm horizontal) is created with a powered surgical drill (e.g. Medtronic Skeeter, Stryker Saber) or Kerrison rongeurs. The lacrimal sac is tented through the upper canaliculus with a Bowman probe and marsupialised with sharp dissection so that the lacrimal sac mucosa is fully laid open into the nasal cavity, creating a wide mucosal flap that apposes the lateral nasal wall mucosa for first-intention healing. Silicone bicanalicular tubes (Crawford or O'Donoghue) are passed through both puncta into the new ostium and tied loosely in the nose under endoscopic vision. Total operating time is 45-90 minutes per side.

Endoscopic DCR was originally popularised by McDonogh and Meiring in 1989 and refined by Tsirbas and Wormald in the early 2000s with the wide-osteotomy mucosal-flap technique that is now standard. NICE issued Interventional Procedure Guidance IPG183 in 2006 supporting the safety and efficacy of endoscopic DCR; BOPSS, ESOPRS and the Royal College of Ophthalmologists have subsequently published practice notes that codify the modern technique. In contemporary published UK and international series, endoscopic and external DCR achieve broadly equivalent anatomical success in primary adult cases (approximately 85-95 per cent), and endoscopic DCR has the substantial cosmetic advantage of no facial scar plus the ability to address concurrent intra-nasal pathology (septal deviation, middle turbinate hypertrophy, polyps) in the same operating session.

UK 2026 endoscopic DCR pricing, in detail

Private endoscopic DCR pricing in the UK is driven by the centre's CQC-registered theatre overhead, consultant oculoplastic seniority and lacrimal volume, anaesthetist seniority, the cost of single-use disposables (silicone bicanalicular tubes, powered surgical drill burrs, sterile drape packs), the post-operative review cadence including tube removal at 8-12 weeks, and where required mitomycin C and powered-drill burrs for revisional cases. Most reputable London providers bundle these components into an all-inclusive per-side fee.

For related oculoplastic and lacrimal pricing and pathways see our ectropion treatment, entropion treatment, private ptosis droopy eyelid surgery cost UK 2026, private blepharoplasty cost UK 2026, private dry eye IPL treatment cost UK and our wider oculoplastics treatments overview.

What a quality UK endoscopic DCR package should include

• Consultant oculoplastic and lacrimal surgeon — a UK GMC-registered consultant ophthalmologist with documented oculoplastic and lacrimal subspecialty fellowship (BOPSS / ESOPRS), active endoscopic DCR practice and a minimum 50 lacrimal procedures per year.
• Full pre-operative lacrimal work-up — best-corrected visual acuity, slit-lamp examination, eyelid and punctal position assessment, fluorescein dye disappearance test (Munk grading), syringing and probing of both lacrimal systems with documentation of hard versus soft stop and complete versus partial reflux, tear meniscus height, tear break-up time, and where indicated dacryocystography or CT dacryocystography.
• In-clinic nasal endoscopy — to assess the lateral nasal wall, middle meatus, septal deviation, middle turbinate hypertrophy and any sinonasal pathology that may need concurrent treatment.
• CQC-registered hospital or day-surgery theatre — with consultant anaesthetist, controlled hypotensive general anaesthesia, full ENT-style nasal endoscopic kit (rigid 0, 30 and 45 degree endoscopes), powered surgical drill (Medtronic Skeeter / Stryker Saber, diamond and cutting burrs) or Kerrison rongeurs, sterile lacrimal probing set, bipolar diathermy, mitomycin C 0.2-0.4 mg/mL availability.
• Silicone bicanalicular tubes — high-quality Crawford or O'Donoghue tubes for 8-12 week intubation of the new ostium.
• Mitomycin C 0.2-0.4 mg/mL — applied to the ostium for 2-3 minutes in revisional cases or where mucosal flap quality is suboptimal.
• Same-day discharge with structured aftercare — topical antibiotic drops, intranasal saline rinses, intranasal corticosteroid spray, oral analgesia, written symptom-warning sheet and the 0800 852 7782 advice line.
• 1-week and 8-12 week follow-up — consultant-led oculoplastic clinic with syringing, nasal endoscopy and tube removal at 8-12 weeks under topical anaesthetic.
• 6-12 month outcome review — repeat fluorescein dye disappearance, syringing and nasal endoscopy to confirm long-term anatomical and symptomatic success.
• Revisional pathway — documented willingness and capability to offer revisional endoscopic DCR with mitomycin C if symptomatic failure occurs (5-15 per cent of primary cases).
• Concurrent oculoplastic capability — the centre should be able to combine DCR with concurrent ectropion / entropion repair, punctoplasty or septoplasty in the same anaesthetic where appropriate.

Evidence base — what the data show

Modern endoscopic DCR has a robust evidence base spanning two decades of UK and international cohort studies, randomised comparisons with external DCR, and large national audits. The headline data should be reviewed together:

• NICE Interventional Procedure Guidance IPG183 (2006) — supports the safety and efficacy of endoscopic DCR for nasolacrimal duct obstruction and recommends its routine use where the operating team has appropriate training in endoscopic technique.
• Tsirbas and Wormald, Ophthalmology 2003 — described the wide-osteotomy mucosal-flap technique that is now the international standard, with 91 per cent anatomical success at 12 months in 79 primary cases.
• Dolman, Ophthalmology 2003 — comparative cohort of endoscopic versus external DCR showing equivalent anatomical and symptomatic success in primary cases with the substantial cosmetic advantage of endoscopic surgery.
• Penttila et al., Acta Ophthalmologica 2015 — prospective cohort of 200 primary endoscopic DCRs with 92 per cent anatomical success at 6 months and 88 per cent symptomatic success by Munk score.
• Smithard et al. and the UK BOPSS lacrimal audit — pooled UK consultant lacrimal surgery data confirming primary endoscopic DCR anatomical success of approximately 85-95 per cent and symptomatic success of approximately 80-92 per cent.
• Revisional endoscopic DCR with mitomycin C — multiple cohorts (Cheng et al.; Liao et al.) report 60-85 per cent success in revisional cases when mitomycin C 0.2-0.4 mg/mL is applied to the ostium for 2-3 minutes.
• Endoscopic versus external DCR (Cochrane / systematic reviews) — broadly equivalent anatomical and symptomatic success in primary adult cases; endoscopic has the advantages of no facial scar, ability to address concurrent intra-nasal pathology, and (in many series) faster recovery; external has occasional advantages in revisional anatomy and very large sac fistulisation.
• BOPSS, ESOPRS and Royal College of Ophthalmologists practice notes — outline modern technique standards, audit cycle expectations and consent points.
• Complication rates — persistent epistaxis 2-5 per cent; orbital fat herniation through the lamina papyracea less than 1 per cent; tube cheesewiring 2-5 per cent; canalicular stenosis less than 5 per cent; ostium granulation 5-15 per cent; CSF leak or anterior cranial fossa injury less than 0.1 per cent in experienced hands.
• Functional / symptomatic endpoint — the clinically meaningful endpoint is patient-reported symptomatic resolution (Munk score reduction by 2 or more), not just an anatomically patent ostium on syringing. Modern UK consent processes should reflect this.

In short: contemporary endoscopic DCR is a well-evidenced, NICE-supported, BOPSS and ESOPRS-codified procedure with approximately 85-95 per cent anatomical and 80-92 per cent symptomatic success in primary cases, very low serious complication rates in experienced hands, and the substantial cosmetic benefit of no facial scar.

Endoscopic DCR versus external DCR versus other options

Honest head-to-head comparison of the watery eye surgical options in 2026:

• Endoscopic DCR — the preferred modern approach for most adult primary nasolacrimal duct obstruction. No facial scar; transnasal approach allows concurrent treatment of septal deviation, middle turbinate hypertrophy or polyps; primary success 85-95 per cent anatomical and 80-92 per cent symptomatic; revisional success 60-85 per cent with mitomycin C; recovery 3-5 days to desk work.
• External skin-incision DCR — the traditional approach via 1-1.5 cm medial canthal skin incision. Equivalent or marginally superior anatomical success in some series (~90-95 per cent); some surgeons still favour it for revisional anatomy, post-traumatic lacrimal anatomy or where a very large sac fistulisation is required. The incision typically heals to an imperceptible line in most patients but is occasionally visible. Recovery is similar to endoscopic DCR.
• Balloon dacryoplasty — lacrimal balloon catheter dilatation of partial obstruction; less invasive, shorter recovery, but substantially lower success (~50-70 per cent in adults); occasionally appropriate for selected partial NLDO where the patient strongly prefers a less invasive option.
• Conjunctivodacryocystorhinostomy (CDCR) with Lester Jones tube — reserved for proximal canalicular obstruction where standard DCR cannot work because the upstream canaliculus is occluded. A lifelong Pyrex glass Jones tube is inserted from the medial canthus to the nasal cavity, bypassing the entire lacrimal system. Useful but requires lifelong tube care, periodic dislodgement and revision.
• Non-surgical management — for non-obstructive epiphora (dry eye paradox, blepharitis, conjunctivochalasis, eyelid malposition with ectropion or entropion, lower lid laxity, punctal stenosis, allergic conjunctivitis) targeted treatment of the underlying cause is often curative without DCR. Surgery is reserved for genuine anatomical obstruction.
• Watchful waiting — reasonable for mildly symptomatic, anatomically partial NLDO where the patient is not troubled by their symptoms. Surgical intervention is offered when symptoms become bothersome, recurrent dacryocystitis develops, or a mucocoele forms.

Who is endoscopic DCR the right choice for?

Endoscopic DCR is indicated for adults with symptomatic anatomical nasolacrimal duct obstruction. Ideal candidacy:

• Confirmed anatomical obstruction — hard stop on syringing with complete reflux from the opposite punctum, and/or radiologically documented obstruction on dacryocystography or CT-DCG.
• Significant symptomatic burden — Munk score 3 or 4 (watery eye most of the time / all of the time); mucus or recurrent dacryocystitis; lacrimal sac mucocoele.
• Non-obstructive causes excluded — eyelid malposition (ectropion, entropion), punctal stenosis, blepharitis, dry eye paradox, conjunctivochalasis, allergic conjunctivitis have been evaluated and addressed where present.
• Open canaliculi above the obstruction — soft stop on syringing or proximal canalicular obstruction is a relative contraindication to standard DCR (CDCR with Lester Jones tube is preferred).
• Fit for general anaesthetic — the procedure is most commonly performed under day-case general anaesthetic; severe anaesthetic risk is a relative contraindication.
• Able and willing to attend follow-up — 1-week and 8-12 week post-operative reviews and tube removal at 8-12 weeks.
• Bilateral cases — bilateral simultaneous endoscopic DCR is straightforward and cost-effective.
• Revisional cases — endoscopic revisional DCR with mitomycin C is the preferred approach for most failed primary DCRs.

Endoscopic DCR is not the right choice for: patients with proximal canalicular obstruction (CDCR with Lester Jones tube is preferred); patients with active acute infectious dacryocystitis (treat with systemic antibiotics first); patients with suspected lacrimal sac tumour (image and biopsy first); patients with active rhinosinusitis (treat first); patients with severe anaesthetic risk that precludes general anaesthetic and who cannot tolerate local anaesthetic endoscopic technique; patients with bleeding diathesis or anticoagulation that cannot be safely managed perioperatively; or patients unable or unwilling to attend the 8-12 week silicone tube removal.

NHS versus private endoscopic DCR

Endoscopic and external DCR are routinely commissioned NHS procedures for symptomatic nasolacrimal duct obstruction and chronic dacryocystitis in accordance with NICE IPG183, BOPSS practice standards and Royal College of Ophthalmologists lacrimal guidance. NHS wait times for routine oculoplastic and lacrimal surgery in 2026 are typically 18 to 40 weeks from referral; the most common patient experience is GP referral to a general ophthalmology clinic, onward referral to a lacrimal subspecialist, then several months on the surgical waiting list. For chronic dacryocystitis (recurrent acute infections, lacrimal mucocoele) and large lacrimal sac fistulae the urgency is greater and NHS prioritisation is usually faster.

The private pathway compresses the timeline to typically 1-3 weeks from initial consultation to consented operating date and offers continuity of named consultant care, the choice of operating surgeon, dedicated CQC oculoplastic theatre time, ring-fenced post-operative review appointments, and the ability to combine DCR with concurrent eyelid surgery (ectropion / entropion / blepharoplasty / ptosis) or septoplasty in the same anaesthetic.

For patients with severely troublesome epiphora, recurrent dacryocystitis or rapidly enlarging mucocoele, the private route is reasonable while NHS waits stretch beyond a clinically acceptable period. For mildly symptomatic patients who are happy to wait, the NHS pathway remains an entirely appropriate route. The choice should be discussed honestly with the consultant.

Private medical insurance and endoscopic DCR

Cover is usual where the policy includes chronic eye disease. Most UK private medical insurers (Bupa, AXA Health, Aviva, Vitality, WPA) cover endoscopic DCR under CCSD procedure code C25.1 (Endoscopic dacryocystorhinostomy) with pre-authorisation. Pre-authorisation requires documented diagnosis (fluorescein dye disappearance test, syringing findings, photographs of any lacrimal swelling, dacryocystography or CT-DCG where indicated), Munk score, prior failed conservative management, consultant clinical justification, the proposed surgical plan (unilateral or bilateral, primary or revisional), and an estimated length of stay (day case). Some insurers limit cover to a fixed benefit per side or per CCSD code and any shortfall is patient-paid. WPA and basic-tier policies may have more restricted cover. The clinic team prepares the pre-authorisation package on your behalf, liaises with the insurer, and clarifies any patient-paid component (excess, shortfall) clearly in writing before booking the operation.

Risks of endoscopic DCR

Honest counselling on endoscopic DCR risks:

• Failure of the ostium with persistent watery eye (5-15 per cent) — the principal counselling point. Treated with revisional endoscopic DCR with mitomycin C 0.2-0.4 mg/mL for 2-3 minutes; second-time success rates 60-85 per cent.
• Persistent post-operative epistaxis (2-5 per cent) — usually settles with conservative measures (head elevation, ice, decongestant nasal spray) or simple anterior nasal packing; very rarely requires return to theatre for bipolar diathermy.
• Silicone tube cheesewiring through the punctum or canaliculus (2-5 per cent) — managed by early tube removal in clinic; usually does not jeopardise long-term ostium patency.
• Canalicular stenosis (less than 5 per cent) — can occur after tube removal; managed by repeat intubation or punctoplasty / canaliculoplasty as appropriate.
• Ostium granulation tissue (5-15 per cent) — managed with intranasal corticosteroid spray escalation, in-office ostium cleaning, mitomycin C application, or in resistant cases ostium curettage / laser revision.
• Adjacent-structure injury (less than 1 per cent in experienced hands) — orbital fat herniation through the lamina papyracea, ethmoid sinus violation, very rare anterior cranial fossa or CSF leak.
• Endophthalmitis or orbital cellulitis — very rare with appropriate technique and post-operative topical antibiotics.
• Anaesthetic risks of general anaesthetic — the usual day-case general anaesthetic risk profile; mitigated by pre-assessment.
• Rare septal perforation or rhinosinusitis — managed with conservative care or in selected cases endoscopic revision.
• No facial scar — the principal cosmetic advantage versus external DCR.

Recovery after endoscopic DCR

Total hospital stay is typically 4-6 hours including pre-operative checks, the 45-90 minute operation per side, and 2-4 hours of anaesthetic recovery. Same-day discharge is routine. There is no facial scar (the entire procedure is transnasal). Discomfort is typically mild and is well-controlled with paracetamol and a short course of co-codamol if needed.

Expect: mild nasal congestion and a small amount of nasal bleeding for 24-48 hours; a metallic taste from any blood swallowed (settles quickly); mild crusting of the operated nostril for 1-2 weeks; the silicone tubes visible at both puncta as a small loop (not painful, not under tension if correctly placed); occasional dark blood-stained nasal mucus in the first 2-3 days. Patients use: topical antibiotic drops (chloramphenicol or moxifloxacin) four times daily for 1-2 weeks; intranasal saline rinses (Sterimar, Neilmed) three to four times daily for 4-6 weeks; intranasal corticosteroid spray (mometasone, fluticasone) once daily for 4-6 weeks to reduce mucosal granulation; oral paracetamol as needed.

Most patients return to desk work in 3-5 days; vigorous exercise, heavy lifting, nose-blowing and air travel are avoided for 2-3 weeks. The silicone tubes are removed at the 8-12 week review in clinic under topical anaesthetic — a brief, painless, no-stitch procedure (the tubes are divided medial canthally with fine scissors and pulled out through the nose under direct endoscopic vision). Sudden severe nasal bleeding, severe pain, fever, vision change, increasing periorbital swelling or sudden visual change should prompt urgent contact with the clinic (0800 852 7782) to exclude orbital cellulitis, retrobulbar haemorrhage or other rare complications. Long-term: a single final outcome review at 6-12 months with repeat fluorescein dye disappearance, syringing and nasal endoscopy is offered to confirm long-term anatomical and symptomatic success.

How to choose a UK clinic for endoscopic DCR

• Consultant credentials — UK GMC registration with oculoplastic and lacrimal subspecialty fellowship (BOPSS / ESOPRS); documented endoscopic DCR experience and a meaningful annual lacrimal case volume (50+ DCRs per year).
• CQC registration — the operating theatre and recovery facility must be CQC-registered and inspected.
• Equipment — rigid 0, 30 and 45 degree nasal endoscopes, powered surgical drill (Medtronic Skeeter or Stryker Saber) with diamond and cutting burrs, sterile lacrimal probing set, bipolar diathermy.
• Adjunct availability — mitomycin C 0.2-0.4 mg/mL for revisional or high-risk primary cases; silicone bicanalicular tubes (Crawford / O'Donoghue) in stock.
• Itemised written quotation — consultant fee, anaesthetist fee, theatre, disposables, silicone tubes, follow-up reviews and tube removal should all be itemised.
• Concurrent oculoplastic capability — the centre should be able to combine DCR with concurrent ectropion / entropion repair, punctoplasty, septoplasty, blepharoplasty or ptosis surgery in the same anaesthetic where appropriate.
• Revisional pathway — documented willingness and capability to offer revisional endoscopic DCR with mitomycin C.
• 24/7 urgent advice line — the 0800 852 7782 line (or equivalent) for urgent post-operative queries.
• Continuity of named consultant — the consultant who consents and operates should lead the 1-week, 8-12 week and 6-12 month reviews.
• Honest written audit of personal outcomes — experienced UK lacrimal surgeons audit their own success and revision rates and are willing to share them.

Frequently asked questions

How much does private endoscopic DCR cost in the UK in 2026?

UK 2026 self-pay private endoscopic DCR is £4,200–£6,500 per side at CQC-registered London oculoplastic and lacrimal centres, all-inclusive. Bilateral simultaneous endoscopic DCR is £7,800–£11,500. Pricing covers consultant assessment, lacrimal work-up, the day-case general anaesthetic operation, silicone intubation, 1-week and 8-12 week reviews, tube removal and the 6-12 month outcome review.

What is endoscopic DCR and how is it different from external DCR?

Endoscopic DCR is performed entirely transnasally using rigid nasal endoscopes — no skin incision, no facial scar, faster recovery, and the ability to address concurrent intra-nasal pathology (septum, middle turbinate, polyps). External DCR is performed via a 1-1.5 cm medial canthal skin incision. Both create a wide bony osteotomy and a marsupialised lacrimal sac into the nose; primary anatomical success rates are broadly equivalent (~85-95 per cent).

Is endoscopic DCR done under general or local anaesthetic?

Most commonly under day-case general anaesthetic with airway secured and controlled hypotensive technique for a still, bloodless field. Local anaesthetic with sphenopalatine ganglion block and infiltration of the lateral nasal wall is feasible in selected patients. Total operating time is 45-90 minutes per side.

What is the success rate?

Approximately 85-95 per cent anatomical success at 6-12 months for primary endoscopic DCR; approximately 80-92 per cent symptomatic success (Munk score reduction). Revisional endoscopic DCR with mitomycin C achieves 60-85 per cent. BOPSS audit and ESOPRS practice notes confirm broadly equivalent success to external DCR in primary cases.

How long do the silicone tubes stay in?

Typically 8-12 weeks. The tubes are removed in clinic under topical anaesthetic — a brief, painless, no-stitch procedure. Some surgeons use shorter intubation (4-6 weeks) or no intubation in primary uncomplicated cases; the evidence on optimal duration is mixed.

What is recovery like?

No facial scar; mild nasal congestion and minor bleeding for 24-48 hours; return to desk work in 3-5 days; no nose-blowing for 2 weeks; no air travel for 1-2 weeks; tubes removed at 8-12 weeks. Topical antibiotic drops, intranasal saline rinses and intranasal steroid spray are used for 4-6 weeks.

What are the risks?

Principal risks: failure with persistent epiphora (5-15 per cent, treated with revisional DCR + mitomycin C), persistent epistaxis (2-5 per cent), tube cheesewiring (2-5 per cent), ostium granulation (5-15 per cent), canalicular stenosis (<5 per cent). Adjacent-structure injury, endophthalmitis, orbital cellulitis and CSF leak are very rare in experienced hands.

Can endoscopic DCR be done on both eyes at the same operation?

Yes — simultaneous bilateral endoscopic DCR is straightforward in experienced hands. Total operating time 75-120 minutes. Bilateral price is £7,800-£11,500, substantially less than two separate unilateral procedures.

Does the NHS cover endoscopic DCR?

Yes. Endoscopic and external DCR are routinely commissioned NHS procedures for symptomatic nasolacrimal duct obstruction and chronic dacryocystitis under NICE IPG183. NHS waits in 2026 are typically 18-40 weeks; the private route compresses to 1-3 weeks.

Will private medical insurance cover endoscopic DCR?

Almost always yes, with pre-authorisation, where the policy covers chronic eye disease. CCSD code C25.1 (Endoscopic dacryocystorhinostomy). Pre-authorisation requires consultant justification, lacrimal work-up, Munk score and imaging where appropriate. The clinic team prepares the pre-authorisation package.

What if I have already had a failed DCR?

Endoscopic revisional DCR with adjunctive mitomycin C 0.2-0.4 mg/mL is the preferred approach. Success rates 60-85 per cent. Common reasons for primary failure include cicatricial ostium scarring, granulation, residual posterior sac mucosa, canalicular obstruction or sump syndrome.

When can I drive after endoscopic DCR?

The day after the operation is usually fine once anaesthetic effects have resolved and the patient feels alert. No eye patch; visual acuity is unaffected. Group 2 (HGV/PSV) licence holders need consultant clearance. Air travel is best avoided for 1-2 weeks.

What if I just have a slightly watery eye — do I really need surgery?

Not necessarily. Treatable non-obstructive causes (eyelid malposition, punctal stenosis, dry eye paradox, blepharitis, conjunctivochalasis, allergic conjunctivitis) are addressed first. DCR is reserved for genuine anatomical obstruction confirmed by syringing and (where indicated) dacryocystography, where the symptomatic burden justifies a day-case general anaesthetic operation. See our related ectropion treatment, entropion treatment and private dry eye IPL cost UK.

Methodology and sources

This UK 2026 patient pricing and pathway guide was prepared by the Eye Surgery Clinic editorial team and reviewed by a UK GMC-registered consultant ophthalmologist with oculoplastic and lacrimal subspecialty interest. Pricing reflects a CQC-registered UK oculoplastic and lacrimal sample audited against published 2025 to 2026 self-pay tariffs from major UK lacrimal providers. Clinical statements are anchored on:

• NICE Interventional Procedure Guidance IPG183 (Endoscopic Dacryocystorhinostomy), National Institute for Health and Care Excellence, 2006.
• Tsirbas A, Wormald PJ. Endonasal dacryocystorhinostomy with mucosal flaps. Ophthalmology 2003.
• Dolman PJ. Comparison of external dacryocystorhinostomy with nonlaser endonasal dacryocystorhinostomy. Ophthalmology 2003.
• Penttila E et al. Prospective evaluation of primary endoscopic endonasal dacryocystorhinostomy. Acta Ophthalmologica 2015.
• British Oculoplastic Surgery Society (BOPSS) lacrimal audit data and practice notes.
• European Society of Ophthalmic Plastic and Reconstructive Surgery (ESOPRS) lacrimal practice notes.
• Royal College of Ophthalmologists Lacrimal Surgery Guidance.
• Cochrane / systematic reviews of endoscopic versus external DCR.
• Cheng et al., Liao et al. and other published series of revisional endoscopic DCR with mitomycin C adjunct.
• Care Quality Commission (CQC) inspection reports for major UK oculoplastic and lacrimal units.
• General Medical Council (GMC) Good Medical Practice and consent guidance.

This page is editorial and educational. It is not personalised medical advice. Endoscopic DCR suitability can only be confirmed by an in-person oculoplastic and lacrimal consultation with fluorescein dye disappearance, syringing and probing, and where indicated dacryocystography.

Book your UK endoscopic DCR consultation

Speak directly to a UK GMC-registered consultant ophthalmologist with oculoplastic and lacrimal subspecialty interest. Same-week consultation slots are usually available. Full lacrimal work-up (fluorescein dye disappearance, syringing and probing, and where indicated dacryocystography) is included in the consultation. Confidential, no-obligation review of whether endoscopic DCR, external DCR, balloon dacryoplasty, CDCR with Lester Jones tube or non-surgical eyelid / dry-eye treatment is right for your watery eye.

Related reading: Oculoplastics treatments overview · Ectropion treatment · Entropion treatment · Private ptosis surgery cost UK 2026 · Private blepharoplasty cost UK 2026 · Private dry eye IPL cost UK